Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1

Inclusion Criteria: * Documented COVID-19 infection (confirmed by NPS positive PCR for SARS-CoV-2) with mild symptoms not requiring hospitalization * First NPS ≤4 days (96 hours) since onset of symptoms * Randomization ≤72 hours since first NPS * Adult Males aged ≥ 50 years * Indication for outpatient treatment but at high risk for complications, at least 1 risk factor (age ≥ 65 years, hypertension, diabetes, cardiovascular disease, active malignancy, COPD) * WHO performance status 0-1 * Adequate hematologic values: haemoglobin ≥ 100 g/L, neutrophils ≥ 1.0 x 10(9)/L, platelets ≥ 150 x 10(9)/L. * Adequate hepatic function: ALT and AST ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN (exception if Gilbert's syndrome ≤ 2.5 x ULN) * Adequate renal function: calculated creatinine clearance ≥ 50 mL/min according to the formula of Cockcroft-Gault * Patient is able to swallow the trial drugs and to comply with trial requirements * Patient agrees not to father a child during participation in the trial and for 3 months thereafter Exclusion Criteria: * Female sex * Moderate to severe COVID-19 symptoms requiring hospitalization * Patients requiring inpatient treatment * Concurrent antiviral drugs or ongoing interventional clinical trial or any off label drug for COVID-19 * Patients with ongoing prostate cancer treatment * Clinically significant cardiovascular disease including: * Myocardial infarction within 6 months prior to registration, * Uncontrolled angina within 3 months prior to registration, * Congestive heart failure NYHA class III or VI * QTc interval \> 480 ms * History of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes) * History of Mobitz II second or third degree heart block without a permanent pacemaker in place * Uncontrolled hypertension as indicated by systolic blood pressure \> 170 mmHg or diastolic blood pressure \> 105 mmHg * Deep venous thrombosis or pulmonary embolism within 6 months * History of cerebrovascular disease * Severe concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrolment. * Known history of HIV, hepatitis B, hepatitis C * Known history of seizures or any conditions that may predispose to seizure. History of loss of consciousness or ischemic cerebrovascular attack within 12 months prior to registration * Concurrent anticoagulation with rivaroxaban or warfarin. Concomitant and continuous use of systemic corticosteroids exceeding 10 mg/day of prednisone or a dose equivalent corticosteroid within 14 days before registration. * Known hypersensitivity to Enzalutamide or hypersensitivity to any of its components * Any concomitant drugs contraindicated for use with Enzalutamide according to the Swissmedic approved product information * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow-up.